More than 25 years of experience from management, business development and finance in the Life Science Industry as well as the global chemical business. Key focus has been to commercialise product innovations in small start ups, mid size and large organisations. He has a deep knowledge in building teams and organisations, forming and managing strategic alliances, fund raising and most aspects of product development in the life science arena. Furthermore through 12 years as the CEO of a public listed company strong experiences in legal affairs, corporate governance and investor relations have been accumulated.
Olov Sterner is an organic chemist specializing in the science of biologically active secondary metabolites. He was awarded the PhD degree in 1985, and after two years as a postoctoral fellow at the University of Bonn in Germany he got a position as researcher at Lund University. 1990 he became lecturer in organic chemistry, and since 1999 he is professor. His research efforts have until now resulted in more than 350 scientific publications in international journals, 23 patent applications and patents, and many conference contributions. He has, alone or with colleagues, written several textbooks in organic chemistry and chemical toxicology, and he is currently the head of the Department of Chemistry.
BG Svensson holds an MSc in Economics from Lund University. He has been hired at Lund University since 2003, today as a senior advisor at LU Holding AB. Current board member positions: Director at Gabather AB, director Nares AB, director at Lunicore Studentkonsult AB, member of advisory consult, Marint Center Simrishamn. BG has also acted as: CEO at Lunds Universitets Utvecklings AB, CEO at Connect Skåne, CEO Science Village Scandinavia AB. Additionally, he has held various leading positions within the bank and finance world, both domestic and international.
Gunilla Ekström became member of the board at Gabather in 2016. Gunilla Ekström is a doctor and attained her PhD from Karolinska Institutet (KI) where she also is an associate professor in biochemical toxicology. She has more than 25 years experience from leading positions in pharmaceutical development in AstraZeneca, Orexo and Karolinska Development, where she had both strategic and operational responsibility for large development teams working with pre-clinical research as well as clinical pharmaceutical development. During her time at AstraZeneca she was a member of the therapeutical area Neurosciences management team, leading a portfolio organisation developing analgesic drug candidates from pre-clinical to clinical studies. Gunilla Ekström also has operational assignments in various SMEs.